Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Adipose-derived mesenchymal stem cell-derived exosomes alleviate overwhelming systemic inflammatory reaction and organ damage and improve outcome in rat sepsis syndrome.

Chang CL., Sung PH., Chen KH., Shao PL., Yang CC., Cheng BC.

Laboratory Study on Systemic / IV, published in Am J Transl Res (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Am J Transl Res (2018)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
29736200
PMCID
PMC5934566
Citations
78

Abstract (original English)

This study tested the hypothesis that healthy adipose-derived mesenchymal stem cell (ADMSC)-derived exosomes (HMSC EXO ) and apoptotic (A) (induced by 12 h hypoxia/12 h starvation)-ADMSC-derived exosomes (AMSC EXO ) were comparably effective at alleviating sepsis syndrome [SS; induced by cecal-ligation and puncture (CLP)]-induced systemic inflammation and reduced organ damage and unfavorable outcomes in rats. SD rats were divided into sham control (SC), SS only, SS + HMSC EXO (100 µg intravenous administration 3 h after CLP), and AMSC EXO . By day 5 after CLP procedure, the mortality rate was significantly higher in SS than in SC and HMSC EXO (all P < 0.01), but it showed no significant different between SC and HMSC EXO , between AMSC EXO and HMSC EXO or between SS and AMSC EXO (P > 0.05). The levels of inflammatory mediators in circulation (CD11 b/c /Ly6G/MIF), bronchioalveolar lavage (CD11 b/c /Ly6G) and abdominal ascites (CD11 b/c /CD14/Ly6G/MIF) were highest in SS, lowest in SC and significantly higher in AMSC EXO than in HMSC EXO (all P < 0.001). The circulating/splenic levels of immune cells (CD34+/CD4+/CD3+/CD8+) were expressed in an identical pattern whereas the T-reg+ cells exhibited an opposite pattern of inflammation among the groups (all P < 0.001). The protein expressions of inflammation (MMP-9/MIF/TNF-α/NF-κB/IL-1β) and oxidative stress (NOX-1/NOX-2/oxidized prote

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research